These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37226898)

  • 1. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
    Shapiro DD; Zacharias NM; Tripathi DN; Karki M; Bertocchio JP; Soeung M; He R; Westerman ME; Gao J; Rao P; Lam TNA; Jonasch E; Perelli L; Cheng EH; Carugo A; Heffernan TP; Walker CL; Genovese G; Tannir NM; Karam JA; Msaouel P
    Clin Transl Med; 2023 May; 13(5):e1267. PubMed ID: 37226898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
    Thibault C; Fléchon A; Albiges L; Joly C; Barthelemy P; Gross-Goupil M; Chevreau C; Coquan E; Rolland F; Laguerre B; Gravis G; Pécuchet N; Elaidi RT; Timsit MO; Brihoum M; Auclin E; de Reyniès A; Allory Y; Oudard S
    Eur J Cancer; 2023 Jun; 186():83-90. PubMed ID: 37054556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
    Strouse JJ; Spevak M; Mack AK; Arceci RJ; Small D; Loeb DM
    Pediatr Blood Cancer; 2005 Apr; 44(4):407-11. PubMed ID: 15602719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
    Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series.
    Ryan A; Tawagi K; VanderVeen N; Matrana M; Vasquez R
    Clin Genitourin Cancer; 2021 Dec; 19(6):e395-e400. PubMed ID: 34565708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.
    Tong S; Si Y; Yu H; Zhang L; Xie P; Jiang W
    Sci Rep; 2017 Jul; 7(1):5599. PubMed ID: 28717191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.
    Wilson NR; Wiele AJ; Surasi DS; Rao P; Sircar K; Tamboli P; Shah AY; Genovese G; Karam JA; Wood CG; Tannir NM; Msaouel P
    Clin Genitourin Cancer; 2021 Dec; 19(6):e401-e408. PubMed ID: 34625389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
    Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
    Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
    Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
    Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
    Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
    Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia.
    Guo N; Azadniv M; Coppage M; Nemer M; Mendler J; Becker M; Liesveld J
    Transl Oncol; 2019 Apr; 12(4):602-613. PubMed ID: 30699367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
    Walsh A; Kelly DR; Vaid YN; Hilliard LM; Friedman GK
    Pediatr Blood Cancer; 2010 Dec; 55(6):1217-20. PubMed ID: 20979179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pevonedistat Suppresses Pancreatic Cancer Growth
    Xu J; Li Z; Zhuo Q; Ye Z; Fan G; Gao H; Ji S; Yu X; Xu X; Liu W; Xu W
    Front Oncol; 2022; 12():822039. PubMed ID: 35155257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.
    Wang J; Wang S; Zhang W; Wang X; Liu X; Liu L; Li L; Liang Y; Yu J; Jeong LS; Jia L; Zhao H; Zhang Y
    Biochem Biophys Res Commun; 2017 Sep; 490(4):1183-1188. PubMed ID: 28669728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
    Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
    J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma.
    Torka P; Mavis C; Kothari S; Belliotti S; Gu J; Sundaram S; Barth M; Hernandez-Ilizaliturri FJ
    EJHaem; 2020 Jul; 1(1):122-132. PubMed ID: 33073261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib.
    Lee AQ; Ijiri M; Rodriguez R; Gandour-Edwards R; Lee J; Tepper CG; Li Y; Beckett L; Lam K; Goodwin N; Satake N
    Front Oncol; 2021; 11():648097. PubMed ID: 33842362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
    Olaizola P; Lee-Law PY; Fernandez-Barrena MG; Alvarez L; Cadamuro M; Azkargorta M; O'Rourke CJ; Caballero-Camino FJ; Olaizola I; Macias RIR; Marin JJG; Serrano-Maciá M; Martinez-Chantar ML; Avila MA; Aspichueta P; Calvisi DF; Evert M; Fabris L; Castro RE; Elortza F; Andersen JB; Bujanda L; Rodrigues PM; Perugorria MJ; Banales JM
    J Hepatol; 2022 Jul; 77(1):177-190. PubMed ID: 35217064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.